Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.64 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250363 | 0.93 | L3MBTL1 (0.62) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2244204 | 0.92 | L3MBTL1 (0.61) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2247187 | 0.91 | L3MBTL1 (0.60) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2244966 | 0.91 | L3MBTL1 (0.60) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2249357 | 0.89 | NPC1 (0.67) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL4648652 | 0.89 | ADAMTS5 (0.63) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2247366 | 0.88 | ADAMTS5 (0.61) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2246740 | 0.87 | CCKBR (0.70) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2246984 | 0.86 | L3MBTL1 (0.60) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 | |
| SCHEMBL2245074 | 0.86 | ADAMTS5 (0.60) | L3MBTL1ADAMTS5ADAMTS4MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | L3MBTL1 4308/4885ADAMTS5 1/4885ADAMTS4 5/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | L3MBTL1 4308/4885ADAMTS5 1/4885ADAMTS4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.